UroGen Pharma Ltd. 8-K

What Happened UroGen Pharma Ltd. and UroGen Pharma Inc. announced on June 2, 2026 that they entered a settlement and license agreement with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. The agreement resolves patent litigation that arose after Teva submitted an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Jelmyto® (mitomycin) in the U.S. Under the deal, UroGen will grant Teva a non‑exclusive license to sell Teva’s generic version of Jelmyto beginning September 15, 2030, if Teva receives FDA approval and absent certain limited customary exceptions. The parties will terminate the existing patent litigation in the U.S. District Court for the District of Delaware. The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Key Details

• Settlement and license announced June 2, 2026 resolving ANDA‑related patent litigation with Teva.
• Teva may begin selling its generic Jelmyto in the U.S. starting September 15, 2030, if approved by the FDA.
• License is non‑exclusive; the agreement includes customary limited exceptions.
• Parties will terminate ongoing Jelmyto patent litigation in the U.S. District Court for the District of Delaware; deal is subject to FTC and DOJ review.
• Filing does not disclose financial terms or royalties.

Why It Matters This agreement establishes a clear timeline for potential generic competition to Jelmyto, which could affect UroGen’s product revenue and market exclusivity beginning in late 2030 if FDA approval is granted. The settlement removes ongoing litigation uncertainty between UroGen and Teva but is still subject to regulatory review and FDA approval, so the outcome is not immediate. Investors should note the absence of disclosed financial terms in the filing and monitor further company disclosures or regulatory actions for details on expected revenue impact.